Can ASP5834 Obliterate the Abnormal KRAS Proteins Driving Many Aggressive Cancers?
Mutations of the KRAS gene cause cancer cells to proliferate out of control. Present in about 25% of all cancers, they are especially prevalent in pancreatic, colorectal and lung cancers, and are associated with disease aggressiveness and poor survival.

An investigational drug called ASP5834, a pan-KRAS degrader, aims not just to block the action of the abnormal proteins produced by the mutated KRAS gene but to wipe them out entirely. A phase 1 clinical trial underway in the U.S., France, Japan and Spain is evaluating the use of this targeted treatment in patients with locally advanced (unresectable) or metastatic solid tumors with a KRAS mutation or amplification.
Roswell Park Comprehensive Cancer Center is the only center in upstate New York offering the trial, which is led by Site Principal Investigator Christos Fountzilas, MD, FACP, Co-Leader of the Gastrointestinal Clinical Disease Team and Associate Director for Solid Tumors, Early Phase Clinical Trials Program.
Sponsored by Astellas Pharma Inc., the study will focus primarily on determining the safety, tolerability and optimal dose of ASP5834, either with or without the targeted immunotherapy panitumumab. Panitumumab is a monoclonal antibody used exclusively in patients with colorectal cancer to stifle tumor growth by blocking epidermal growth factor receptor (EGFR).
In part 1 of the study, participants will receive increasing doses of either ASP5834 alone or — for those with colorectal cancer — ASP5834 in conjunction with panitumumab. In part 2, additional patient cohorts will be treated with the recommended dose of ASP5834, given alone or in combination with panitumumab, as determined in part 1.
